stelara subcutaneous injection 45mg (ステラーラ皮下注45mgシリンジ)
janssen pharmaceutical k.k. - ustekinumab (genetical recombination) - injection
stelara subcutaneous injection 45mg (ステラーラ皮下注45mgシリンジ)
mitsubishi tanabe pharma corporation - ustekinumab (genetical recombination) - injection
lumicef subcutaneous injection 210 mg syringe
kyowa kirin malaysia sdn. bhd. - brodalumab -
kyntheum
leo pharma a/s - brodalumab - psoriasis - immunosuppressants - kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
cosentyx
novartis new zealand ltd - secukinumab 150mg; - powder for injection - 150 mg - active: secukinumab 150mg excipient: histidine hydrochloride monohydrate nitrogen polysorbate 80 sucrose - cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.
cosentyx
novartis new zealand ltd - secukinumab 150 mg/ml; - solution for injection - 150 mg/ml - active: secukinumab 150 mg/ml excipient: histidine hydrochloride monohydrate methionine nitrogen polysorbate 80 trehalose dihydrate water for injection - cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.
fraizeron 150mgml solution for injection in pre-filled pen
novartis corporation (malaysia) sdn. bhd. - secukinumab -
fraizeron 150mg powder for solution for injection
novartis corporation (malaysia) sdn. bhd. - secukinumab -
cosentyx 150mgml solution for injection in pre-filled syringe
novartis corporation (malaysia) sdn. bhd. - secukinumab -
cosentyx powder for solution for injection 150mgvial
novartis (singapore) pte ltd - secukinumab - injection, powder, for solution - secukinumab 150 mg/vial